Job cuts at Boehringer Ingelheim: severance pay and your rights
What employees need to know now: status of the cuts, severance practice and your rights.
Updated on 07/10/2026
RevenueRevenue
€27.8 bn
Group, financial year
HeadquartersHeadquarters
Ingelheim
Rhineland-Palatinate
Stock exchange listingStock exchange
nicht börsennotiert (Familienbesitz)
Industry Pharmaceuticals
Severance factorSeverance factor
0.7 to 1.2
Monthly salaries per year
The factor range is our estimate, not a commitment by the company. The actual severance pay depends on the individual case, in particular length of service, age and pay grade.
Severance pay at Boehringer Ingelheim
Severance factor
0.7 to 1.2
Monthly salaries per year of employment
Editorial estimate- 0
- 0,5
- 1,0
- 1,5
- 2,0
Vertical line: rule of thumb 0.5, no legal entitlement
Base amount
not known
Negotiating partner
Works council and IG BCE
Current arrangements
Boehringer Ingelheim currently has no job cuts programme in Germany and therefore no current social plan (Sozialplan). In earlier programmes, the company relied on socially responsible solutions and wanted to avoid redundancy dismissals (betriebsbedingte Kündigungen); at the Vienna site, a social plan was agreed with the works council (Betriebsrat) in 2026.
Assessment of the severance factor
We derive a severance factor of 0.9, with a range of 0.7 to 1.2. This is supported by the collectively bargained chemical and pharmaceutical sector with strong employee representation, the above-average salary levels in research, production and administration, and the very good earnings position of the family-owned company.
The factor is an assessment that we derive from the sector, region, co-determination and economic situation, and is not a commitment by the company. What can ultimately be achieved depends on your specific case, in particular length of service, age and any special protection against dismissal. Other circumstances of the individual case also play a role.
The factor is our estimate, derived from industry, region, co-determination and economic situation, and is not a commitment by the company. Length of service, age and special protection against dismissal can shift the result considerably.
Severance calculator
What you could be entitled to at Boehringer Ingelheim
Possible severance pay
–
Special protection against dismissal?
Non-binding guidance based on the standard formula, not legal advice. There is only a right to severance pay in exceptional cases; the actual amount depends on the individual case, for example on age, maintenance obligations and whether the dismissal is valid. AbfindungsHero puts you in touch with employment law firms and does not provide legal services itself.
Headcount development
Boehringer Ingelheim, worldwide
Source: annual reports
Average number of employees over the year, not a reference date, headcount without full-time conversion (Highlights Report 2025): 54,346 worldwide (2024: 54,543), Europe 31,387, the Americas 13,463, Asia, Australia and Africa 9,496. The company does not publish a figure for Germany.;; 2025 · 54,346 employees worldwide as an annual average, no figure for Germany published. Documented figures are 45,700 employees as an annual average in 2016, 51,944 in 2020 and around 52,400 in 2021 from company announcements, as well as 54,543 and 54,346 for 2024 and 2025. For 2017 to 2019 and for 2022 and 2023, no publicly available annual figures exist. Scale starts at 32,000, not at zero.
Timeline of the job cuts
- Investment freeze of €900 million in Germany In June 2026, Boehringer Ingelheim halted planned investments of 900 million euros in Germany. This also affects the largest research site, Biberach an der Riß, with around 8,000 employees. Details are not known. This is not a job cut, but it shifts growth to other locations; in the first half of 2026, the group grew by 16.2 per cent to €15.8 bn in revenue.
Boehringer Ingelheim: job cuts, severance pay and employees' rights
No job cuts programme at Boehringer Ingelheim, but an investment freeze
No job cuts in Germany have currently been announced at Boehringer Ingelheim. The pharmaceutical group is growing strongly: in the first half of 2026, currency-adjusted revenue rose by 16.2 per cent to 15.8 billion euros, of which 13.1 billion came from the human pharma business. In 2025, the family-owned company employed an annual average of 54,346 people worldwide, 31,387 of them in Europe. Boehringer does not publish a figure for Germany. Revenue rose to 27.751 billion euros in 2025, and 6.353 billion euros went into research and development.
The relevant news for German sites
In June 2026, Boehringer halted planned investments of 900 million euros in Germany. This also affects its largest research site, Biberach an der Riß, where around 8,000 people work and the company is the town's largest employer. Details are not yet known. Germany head Médard Schoenmaeckers justifies this by pointing to pharmaceutical policy and sees the industry in Germany as deprioritised. An investment freeze is not a job cut, but it shifts growth to other locations.
How Boehringer has made cuts in the past
The company has experience with socially responsible job cuts. In 2014, it announced that it would save 15 per cent of costs nationwide, with almost 1,000 jobs mentioned at the time; redundancy dismissals were to be avoided. In 2016, almost 900 jobs were cut in medicine production, mainly at the Ingelheim headquarters and to a lesser extent in Biberach and Dortmund, because simpler products were relocated abroad. The Vienna site currently shows how the group proceeds: after production of a vaccine component was stopped, around 150 of 1,800 biopharma employees were affected there; about half were kept on within the company, and a social plan was agreed with the works council for the others.
Are you negotiating a separation with Boehringer Ingelheim?
How much is possible depends on your specific case. An employment lawyer from our network will give you an initial assessment in a free first consultation; with the severance pay calculator you can see the order of magnitude beforehand.
Affected by job cuts at Boehringer Ingelheim?
Whether an offer is fair can only be judged on the specific case. An employment law firm will assess your situation free of charge.